Literature DB >> 16758118

CHEK2 1100delC mutation is frequent among Russian breast cancer patients.

Elena V Chekmariova1, Anna P Sokolenko, Konstantin G Buslov, Aglaya G Iyevleva, Yulia M Ulibina, Maxim E Rozanov, Natalia V Mitiushkina, Alexandr V Togo, Dmitry E Matsko, Dmitry A Voskresenskiy, Oleg L Chagunava, Peter Devilee, Cees Cornelisse, Vladimir F Semiglazov, Evgeny N Imyanitov.   

Abstract

This study was aimed to assess the role of CHEK2 1100delC mutation in breast cancer (BC) predisposition in Russia. The 1100delC allele was detected in 14/660 (2.1%) unilateral BC cases and in 8/155 (5.2%) patients with the bilateral form of the disease, but only in 1/448 (0.2%) middle-aged control females and in none of 373 elderly tumor-free women. The obtained data point at potentially high clinical relevance of CHEK2 1100delC testing in females of Russian origin and warrant similar case-control studies in ethnically and geographically related regions, especially in Ukraine, Belarus and Baltic countries.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16758118     DOI： 10.1007/s10549-006-9227-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  13 in total

1.  Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Authors:  Evgeny N Suspitsin; Grigory A Yanus; Anna P Sokolenko; Olga S Yatsuk; Olga A Zaitseva; Alexandr A Bessonov; Alexandr O Ivantsov; Valeria A Heinstein; Valery F Klimashevskiy; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2014-01-12       Impact factor: 3.064

2.  Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort.

Authors:  Aleksander Myszka; Pawel Karpinski; Ryszard Slezak; Halina Czemarmazowicz; Agnieszka Stembalska; Justyna Gil; Izabela Laczmanska; Damian Bednarczyk; Elzbieta Szmida; Maria Malgorzata Sasiadek
Journal:  J Appl Genet       Date:  2010-12-01       Impact factor: 3.240

3.  The CHEK2*1100delC Mutation and Adolescent Breast Cancer: A Case Report of Breast Cancer in a 19-Year-Old and a Review of the Literature.

Authors:  Tahereh Soleimani; Abigail J Engwall; Corrie Bourdon; Mohammad A Torabi; Thais Fortes
Journal:  Breast Care (Basel)       Date:  2021-03-08       Impact factor: 2.860

4.  Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer.

Authors:  Dapeng Ding; Ying Zhang; Xiaofeng He; Wei Meng; Wenli Ma; Wenling Zheng
Journal:  Breast Cancer Res       Date:  2012-04-20       Impact factor: 6.466

5.  Hereditary breast-ovarian cancer syndrome in Russia.

Authors:  A P Sokolenko; A G Iyevleva; N V Mitiushkina; E N Suspitsin; E V Preobrazhenskaya; E Sh Kuligina; D A Voskresenskiy; O S Lobeiko; N Yu Krylova; T V Gorodnova; K G Buslov; E M Bit-Sava; G D Dolmatov; N V Porhanova; I S Polyakov; S N Abysheva; A S Katanugina; D V Baholdin; G A Yanus; A V Togo; V M Moiseyenko; S Ya Maximov; V F Semiglazov; E N Imyanitov
Journal:  Acta Naturae       Date:  2010-10       Impact factor: 1.845

6.  Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.

Authors:  Anna P Sokolenko; Maxim E Rozanov; Natalia V Mitiushkina; Natalia Yu Sherina; Aglaya G Iyevleva; Elena V Chekmariova; Konstantin G Buslov; Evgeny S Shilov; Alexandr V Togo; Elena M Bit-Sava; Dmitry A Voskresenskiy; Oleg L Chagunava; Peter Devilee; Cees Cornelisse; Vladimir F Semiglazov; Evgeny N Imyanitov
Journal:  Fam Cancer       Date:  2007-02-28       Impact factor: 2.446

7.  CHEK2 1100 delC mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Daria N Ponomariova; Natalia Yu Sherina; Natalia Yu Ogorodnikova; Denis A Logvinov; Natalia V Porhanova; Oksana S Lobeiko; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Suspitsin; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

8.  Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.

Authors:  Olivia Fletcher; Nichola Johnson; Isabel Dos Santos Silva; Outi Kilpivaara; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Marijke Wasielewski; Hanne Meijers-Heijerboer; Annegien Broeks; Marjanka K Schmidt; Laura J Van't Veer; Michael Bremer; Thilo Dörk; Elena V Chekmariova; Anna P Sokolenko; Evgeny N Imyanitov; Ute Hamann; Muhammad U Rashid; Hiltrud Brauch; Christina Justenhoven; Alan Ashworth; Julian Peto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

9.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Authors:  L Mellemkjaer; C Dahl; J H Olsen; L Bertelsen; P Guldberg; J Christensen; A-L Børresen-Dale; M Stovall; B Langholz; L Bernstein; C F Lynch; K E Malone; R W Haile; M Andersson; D C Thomas; P Concannon; M Capanu; J D Boice; J L Bernstein
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

10.  High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.

Authors:  Evgeny N Suspitsin; Nathalia Yu Sherina; Daria N Ponomariova; Anna P Sokolenko; Aglaya G Iyevleva; Tatyana V Gorodnova; Olga A Zaitseva; Olga S Yatsuk; Alexandr V Togo; Nathalia N Tkachenko; Grigory A Shiyanov; Oksana S Lobeiko; Nadezhda Yu Krylova; Dmitry E Matsko; Sergey Ya Maximov; Adel F Urmancheyeva; Nathalia V Porhanova; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-02-25       Impact factor: 2.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.